Developing novel prognostic biomarkers for multivariate fracture risk prediction algorithms.

Area of Science:

• Osteoporosis and fracture risk assessment.
• Biomarker development and validation.
• Health informatics and predictive modeling.

Background:

• Multivariate algorithms like FRAX® and QFractureScores aid fracture risk prediction.
• Current prognostic tools include DXA, QUS, and genomic/biochemical markers.
• Incorporating novel biomarkers can enhance predictive accuracy.

Purpose of the Study:

• To review existing fracture risk prediction algorithms (FRAX®, QFractureScores) for the UK population.
• To discuss current prognostic tools and emerging biomarkers for osteoporosis.
• To highlight key factors for developing and validating new biomarkers for risk algorithms.

Main Methods:

• Literature review of multivariate prediction algorithms and prognostic tools.
• Discussion of data requirements for new biomarker development (prospective data, stability, storage).
• Analysis of performance evaluation measures for multivariate algorithms.

Main Results:

• FRAX® and QFractureScores are established UK-specific fracture risk algorithms.
• New biomarkers require prospective data, stability, and proper storage for validation.
• Traditional AUC measures have limitations; NRI and IDI are superior for evaluating new markers.

Conclusions:

• Successful integration of new biomarkers into algorithms like FRAX® necessitates robust validation.
• Prospective data collection and rigorous stability testing are essential for biomarker development.
• Advanced performance metrics (Net Reclassification Index, Integrated Discrimination Improvement) are vital for assessing biomarker utility.